Introducing Libracaine® Dental1 LIDOCAINE HCL 2% / EPINEPHRINE 1:100,000 / SODIUM BICARBONATE 0.7% Less painful, faster-acting, more reliable2 Supplied in a standard dental cartridge üNo new equipment, no new protocols Patented cartridge technology3 A pH-balanced version of the most often-used anesthetic4 in dentistry üSame safety profile, 24-month shelf life View a 60-second technology demonstration video 1LIBRACAINE HAS NOT BEEN APPROVED BY FDA AND IS NOT AVAILABLE FOR SALE;22018 Meta-analysis: Guo et al from University of Southern California School Of Dentistry concluded: “Buffered lidocaine significantly decreased onset time and injection pain (VAS) compared with non-buffered lidocaine in inferior alveolar nerve block.”; 2017 Clinical Study: Phero et al from University Of North Carolina School Of Dentistry concluded: “Buffered lidocaine reduces the pain on injection with a maxillary field block and results in similar lengths of pulpal anesthesia as non-buffered 2% lidocaine.” 2017 Clinical Study: Warren et al from University Of North Carolina School Of Dentistry concluded: “After mandibular nerve block, buffered 1% lidocaine can produce similar duration of pulpal anesthesia as non-buffered 2% lidocaine and lower pain on injections.”; 2019 Meta-analysis: Kattan et al from University Of Pennsylvania School Of Dentistry concluded: “Buffered local anesthetics have 2.29 times greater likelihood of achieving successful anesthesia [in pulpally involved teeth].” 3BPI owns the following granted patents and pending patent applications: U.S. Patent No. 11,305,064 (issued April 19th, 2022); U.S. Application No. 17/722,016; International PCT Application No. PCT/IB2018/052598; Canadian Application No. 3,111,347 (Canadian National Phase of PCT/IB2018/052598); European Application No. 18897951.2 (European Regional Phase of PCT/IB2018/052598); Japanese Application No. 2020-556351 (Japanese National Phase of PCT/IB2018/052598); Korean Application No. 10-2020-7021685 (Republic of Korea National Phase of PCT/IB2018/052598); U.S. Application No. 16/655,362; U.S. Application No. 63/233,879; BPI also owns one trademark application, U.S. Application No. 88/198,808, pending for the LIBRACAINE mark.; 4SDM Northcoast report, “Injectable Carpules Market Size Analysis, United States, Canada, Mexico, 2019 Units”, July 15, 2021. PRIVATE & CONFIDENTIAL